t-BuN(Cbz)CH2CHO | 1207285-18-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: t-BuN(Cbz)CH2CHO
• 英文别名: benzyl N-tert-butyl-N-(2-oxoethyl)carbamate
• CAS: 1207285-18-4
• 化学式: C₁₄H₁₉NO₃
• 分子量: 249.31
• InChiKey: LERXJBCSEWOZFU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  18
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  46.6
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (4S,4aS,5aR,12aS)-8-amino-13-(dimethylamino)-9-[ (dimethylamino)methyl]-4a-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-10-fluoro-11a,12,12a,13-tetrahydro-5-hydroxy-3,7-bis(phenylmethoxy)-naphthaceno[2,3-d]isoxazole-4,6(4aH,11H)-dione 、 t-BuN(Cbz)CH2CHO 在 溶剂黄146 、 三乙酰氧基硼氢化钠 作用下， 以 1,2-二氯乙烷 为溶剂， 反应 2.0h， 生成
  参考文献：
  名称：

  Fluorocyclines. 2. Optimization of the C-9 Side-Chain for Antibacterial Activity and Oral Efficacy

  摘要：

  Utilizing a fully synthetic route to tetracycline analogues, the C-9 side-chain of the fluorocyclines was optimized for both antibacterial activity and oral efficacy. Compounds were identified that overcome both efflux (tet(K), tet(A)) and ribosomal protection (tet(M)) tetracycline-resistance mechanisms and are active against Gram-positive and Gram-negative organisms. A murine systemic infection model was used as an oral efficacy screen to rapidly identify compounds with oral bioavailability. Two compounds were identified that exhibit both oral bioavailability in rat and clinically relevant bacterial susceptibility profiles against major respiratory pathogens. One compound demonstrated oral efficacy in rodent lung infection models that was comparable to marketed antibacterial agents,

  DOI：

  10.1021/jm201467r

文献信息

• Fluorocyclines. 2. Optimization of the C-9 Side-Chain for Antibacterial Activity and Oral Efficacy
  作者：Roger B. Clark、Diana K. Hunt、Minsheng He、Catherine Achorn、Chi-Li Chen、Yonghong Deng、Corey Fyfe、Trudy H. Grossman、Philip C. Hogan、William J. O’Brien、Louis Plamondon、Magnus Rönn、Joyce A. Sutcliffe、Zhijian Zhu、Xiao-Yi Xiao

  DOI：10.1021/jm201467r

  日期：2012.1.26

  Utilizing a fully synthetic route to tetracycline analogues, the C-9 side-chain of the fluorocyclines was optimized for both antibacterial activity and oral efficacy. Compounds were identified that overcome both efflux (tet(K), tet(A)) and ribosomal protection (tet(M)) tetracycline-resistance mechanisms and are active against Gram-positive and Gram-negative organisms. A murine systemic infection model was used as an oral efficacy screen to rapidly identify compounds with oral bioavailability. Two compounds were identified that exhibit both oral bioavailability in rat and clinically relevant bacterial susceptibility profiles against major respiratory pathogens. One compound demonstrated oral efficacy in rodent lung infection models that was comparable to marketed antibacterial agents,